Table 3.
Clinical Characteristics associated with rising IL-18 levels
| Clinical Characteristic | Rising IL-18 (237 subjects) |
Stable or falling IL-18 (351 subjects) | P value | |
|---|---|---|---|---|
| Age (years) | 55 (41, 68) | 56 (44, 65) | >.2 | |
| Female gender | 116 (49%) | 180 (51%) | >.2 | |
| White Race | 191 (81%) | 274 (78%) | >.2 | |
| APACHE III Score | 91 (71, 114) | 91 (75, 110) | >.2 | |
| Shock at baseline | 117 (54%) | 145 (46%) | .04 | |
| P:F<200 | 164 (74%) | 234 (72%) | >.2 | |
| Baseline CRP (mg/dL) | 23 (13, 31) | 22 (12, 31) | >.2 | |
| Randomization to statin | 137 (58%) | 153 (44%) | <.001 | |
| IV or po steroids ≥ 20 mg on Day 1 | 42 (20%) | 95 (31%) | .01 | |
| AKI | 132 (56%) | 159 (45%) | .01 | |
| ESLD | 13 (5%) | 15 (4%) | >.2 | |
| Malignancy | 33 (14%) | 40 (11%) | >.2 | |
| Baseline IL-18 (pg/ml) | 468 (348, 637) | 621 (448, 840) | <.001 | |
Values as N(%) or Median (IQR).
1
Malignancy= lymphoma, leukemia, or metastatic cancer. “Rising” defined by increase of IL18 by 10% at Day 3, compared with the 353 subjects with stable or falling values at Day 3. P values are for Wilcoxon’s rank sum for continuous variables, Fisher’s exact test for categorical variables. Clinical characteristics significantly associated with rising IL18 highlighted in BOLD.